Results 181 to 190 of about 198,936 (307)

Vision Impairment, Insurance Coverage, and Out-of-Pocket Spending.

JAMA Netw Open
Sultana MS, McInerney M, Boudreaux M, Yu F, Coleman AL, Lipton B.   +5 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Insurance Coverage and Perceived Access to Care Among Rural Adults: A Cross-Sectional Study Using Andersen's Behavioral Model. [PDF]

Public Health Nurs
Ketel C, Lindley LC.
europepmc   +1 more source

Health-Insurance Coverage [PDF]

New England Journal of Medicine, 1959
openaire   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Variability in Insurance Coverage for Adult Voice Therapy in The United States of America. [PDF]

Laryngoscope
Xiao KB, Goldenberg CB, Gates CK, Gilbert MR.   +3 more
europepmc   +1 more source

Partial Deposit Insurance and Moral Hazard in Banking

: Countries with deposit insurances differ significantly on how much protection their insurance provides. We study the optimal coverage limit in a model of deposit insurance with capital requirements and risk sensitive premia to prevent moral hazard ...
Li, Gan, Wen-Yao, Wang
core   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Impact of Delisting Non-Prescription Medicines from Health Insurance Coverage on Physicians' Prescribing Behaviour in Iran: A Qualitative Study. [PDF]

J Res Pharm Pract
Raeis Zadeh MM, Borhani M, Soleymani F, Yazdizadeh B, Nikfar S.   +4 more
europepmc   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source